Epifanio Garavito-Sanchez
Lima, LMA, Peru
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: November 13, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: March 29, 2025
Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
Journal: American journal of respiratory and critical care medicine
Published: January 16, 2019
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
Journal: American journal of respiratory and critical care medicine
Published: June 30, 2018
Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: January 07, 2017
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
Journal: BMC infectious diseases
Published: May 04, 2016
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.
Journal: Bulletin of the World Health Organization
Published: March 05, 2015
Delamanid for multidrug-resistant pulmonary tuberculosis.
Journal: The New England journal of medicine
Published: June 08, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026